General Information of Drug (ID: DMFXUT8)

Drug Name
Oxymetholone
Synonyms oxymetholone; Anasterone; 434-07-1; HMS3393H15
Indication
Disease Entry ICD 11 Status REF
Aplastic anemia 3A70 Approved [1]
Aregenerative anemia N.A. Approved [2]
Diamond-Blackfan anemia N.A. Approved [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 332.5
Logarithm of the Partition Coefficient (xlogp) 4.4
Rotatable Bond Count (rotbonds) 0
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 15.038 micromolar/kg/day [4]
Chemical Identifiers
Formula
C21H32O3
IUPAC Name
(2Z,5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-2-(hydroxymethylidene)-10,13,17-trimethyl-1,4,5,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
Canonical SMILES
C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(C/C(=C/O)/C(=O)C4)C
InChI
InChI=1S/C21H32O3/c1-19-11-13(12-22)18(23)10-14(19)4-5-15-16(19)6-8-20(2)17(15)7-9-21(20,3)24/h12,14-17,22,24H,4-11H2,1-3H3/b13-12-/t14-,15+,16-,17-,19-,20-,21-/m0/s1
InChIKey
ICMWWNHDUZJFDW-DHODBPELSA-N
Cross-matching ID
PubChem CID
5281034
ChEBI ID
CHEBI:7864
CAS Number
434-07-1
DrugBank ID
DB06412
TTD ID
D0Q6NZ
INTEDE ID
DR1225
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Steroid 5-alpha-reductase 1 (SRD5A1)
Main DME
DEOG15F S5A1_HUMAN Substrate [5]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
11-beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) OTHF4H9U DHI2_HUMAN Gene/Protein Processing [6]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Gene/Protein Processing [7]
Interleukin-7 (IL7) OTT6YSKM IL7_HUMAN Gene/Protein Processing [7]
Kit ligand (KITLG) OTB9AVQ4 SCF_HUMAN Gene/Protein Processing [7]
Thyroid peroxidase (TPO) OTJJLL20 PERT_HUMAN Gene/Protein Processing [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Oxymetholone (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Oxymetholone and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [8]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Oxymetholone and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [9]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Oxymetholone and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [10]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Oxymetholone and Cannabidiol. Epileptic encephalopathy [8A62] [11]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Oxymetholone and Brentuximab vedotin. Hodgkin lymphoma [2B30] [12]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Oxymetholone and Teriflunomide. Hyper-lipoproteinaemia [5C80] [13]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Oxymetholone and BMS-201038. Hyper-lipoproteinaemia [5C80] [14]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Oxymetholone and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [15]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Oxymetholone and Idelalisib. Mature B-cell leukaemia [2A82] [16]
Carfilzomib DM48K0X Major Additive thrombogenic effects by the combination of Oxymetholone and Carfilzomib. Multiple myeloma [2A83] [8]
⏷ Show the Full List of 10 DDI Information of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Oxymetholone FDA Label
3 BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
4 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5 Androgen physiology. Semin Reprod Med. 2006 Apr;24(2):71-7.
6 The anabolic androgenic steroid fluoxymesterone inhibits 11beta-hydroxysteroid dehydrogenase 2-dependent glucocorticoid inactivation. Toxicol Sci. 2012 Apr;126(2):353-61.
7 Direct and indirect effects of androgens on survival of hematopoietic progenitor cells in vitro. J Korean Med Sci. 2005 Jun;20(3):409-16. doi: 10.3346/jkms.2005.20.3.409.
8 Cerner Multum, Inc. "Australian Product Information.".
9 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
10 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
11 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
12 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
13 Canadian Pharmacists Association.
14 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
15 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
16 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.